Plus Therapeutics' Groundbreaking Research at the CNS Annual Meeting
AUSTIN, Texas — Plus Therapeutics, Inc. (NASDAQ: PSTV), a leading clinical-stage pharmaceutical company, is set to share important results from its ReSPECT-GBM Phase 2 trial at the upcoming Congress of Neurological Surgeons Annual Meeting. This prestigious event will take place from September 28 to October 2 in Houston, Texas, attracting top experts in neurology and neurosurgery.
Key Details of the Trial Presentation
The focus of the presentation will be on treating recurrent glioblastoma (rGBM), a devastating type of brain cancer affecting thousands of people each year. The highlight will be an update on the innovative application of Rhenium-186 Obisbemeda, a specially formulated therapeutic radiopharmaceutical designed to utilize advanced delivery methods to tackle this critical health challenge.
About the Presentation
Dr. John Floyd, a respected Associate Professor and Chairman of Neurosurgery at UT Health Science San Antonio, will be presenting a session titled, “Treatment of Recurrent Glioblastoma via Convection Enhanced Delivery with Rhenium-186 Obisbemeda: ReSPECT-GBM Phase 2 Trial Update.” This session is scheduled for Monday, September 30, 2024, from 7:00 to 8:30 a.m. CDT, at Room 310C in the George R. Brown Convention Center.
What is Recurrent Glioblastoma?
Recurrent GBM ranks among the most aggressive and deadly forms of brain cancer, with approximately 15,000 new diagnoses occurring annually in the United States. Unfortunately, the outlook for those diagnosed is quite bleak; the average life expectancy is under two years, and the five-year survival rate hovers around a mere 5%. Unfortunately, the current treatment options for this type of cancer are limited, creating a pressing need for innovative therapeutic approaches.
Statistical Overview
The challenges posed by GBM are exacerbated by its high likelihood of recurrence. Approximately 90% of patients will see their tumors return in or near the original location. Sadly, existing FDA-approved treatments do not offer significant survival benefits, compelling both healthcare providers and patients to seek out novel solutions.
Introducing Rhenium-186 Obisbemeda
Rhenium-186 Obisbemeda is a significant advancement in targeted radiotherapy, engineered to optimize radiation delivery directly to CNS tumors. This revolutionary injectable therapy uses the short half-life of Rhenium-186 to create a powerful method for delivering localized treatment while reducing the risk of affecting surrounding healthy tissues.
How It Operates
This cutting-edge treatment employs Convection Enhanced Delivery (CED), a minimally invasive technique that allows for the direct infusion of therapeutic agents into brain tumors via specialized catheters. This targeted delivery system aims to boost treatment effectiveness while improving patient outcomes by confining the impact to the tumor site.
Looking Ahead for Plus Therapeutics
Plus Therapeutics is dedicated to transforming the treatment landscape for challenging central nervous system cancers. Their research is backed by partnerships with the National Cancer Institute and the Cancer Prevention & Research Institute of Texas, underscoring their commitment to driving innovation in oncology.
Company Overview
Plus Therapeutics strives to develop targeted radiotherapeutics that enhance cancer treatment results through innovative approaches. The company is working to expand its pipeline of drug candidates and is positioned to make meaningful contributions to the fields of neurology and oncology.
Frequently Asked Questions
What is the primary focus of Plus Therapeutics at the CNS Annual Meeting?
Plus Therapeutics will be sharing important findings from their ReSPECT-GBM Phase 2 trial, focusing on new treatment strategies for recurrent glioblastoma.
Who will present the findings from the ReSPECT-GBM trial?
Dr. John Floyd, a distinguished Associate Professor and Chairman of Neurosurgery, will lead the presentation during the session.
What exactly is Rhenium-186 Obisbemeda?
Rhenium-186 Obisbemeda is an innovative injectable radiotherapy designed to provide targeted radiation treatment directly to CNS tumors, aiming to improve patient outcomes.
Why is recurrent glioblastoma considered particularly challenging?
Recurrent glioblastoma is extremely aggressive, characterized by poor prognosis and survival rates. Current approved treatments offer limited benefits along with substantial side effects.
What is the Convection Enhanced Delivery method?
The CED method involves the surgical insertion of small catheters into brain tumors, enabling direct and targeted infusion of therapeutic agents, thereby enhancing treatment effectiveness and minimizing damage to healthy tissues.
